

| Therapy | Mechanism | Complete Response (3 months) | Complete Response (6 months) | Complete Response (12 months) |
|---|--|---|---|--|
| Gemcitabine + Docetaxel (Gem-Doce) | Sequential intravesical chemotherapy that damages tumor DNA (gemcitabine) and disrupts cell division (docetaxel) | ~65–70% | ~55–60% | ~40–45% |
| Adstiladrin | Gene therapy delivering interferon- α via modified adenovirus to stimulate immune attack on tumor cells | ~53% | ~40–45% | ~24–30% |
| Anktiva + BCG | IL-15 superagonist that activates NK cells and CD8+ T cells to enhance immune response | ~60–70% | ~55–60% | ~45–50% |
| Inlexzo | Intravesical drug-delivery device that continuously releases gemcitabine in the bladder over several weeks | ~80–82% | ~65–70% | ~50–55% |